WRNIP1 Protects Reversed DNA Replication Forks from SLX4-Dependent Nucleolytic Cleavage
Bartlomiej Porebski, Sebastian Wild, Sandra Kummer, Sarah Scaglione, Pierre-Henri Gaillard, Kerstin Gari

To cite this version:
Bartlomiej Porebski, Sebastian Wild, Sandra Kummer, Sarah Scaglione, Pierre-Henri Gaillard, et al.. WRNIP1 Protects Reversed DNA Replication Forks from SLX4-Dependent Nucleolytic Cleavage. iScience, Elsevier, 2019, 21, pp.31-41. 10.1016/j.isci.2019.10.010. hal-03091046

HAL Id: hal-03091046
https://hal.archives-ouvertes.fr/hal-03091046
Submitted on 30 Dec 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
WRNIP1 Protects Reversed DNA Replication Forks from SLX4-Dependent Nucleolytic Cleavage

**HIGHLIGHTS**

WRNIP1, as BRCA2, protects stalled replication forks downstream of fork reversal

WRNIP1 and BRCA2 act in two different branches of the fork protection pathway

WRNIP1 protects from SLX4-mediated nucleolytic cleavage, possibly by direct binding

Fork protection function is specific to the shorter isoform of WRNIP1
WRNIP1 Protects Reversed DNA Replication Forks from SLX4-Dependent Nucleolytic Cleavage

Bartlomiej Porebski, 1,3,* Sebastian Wild, 1 Sandra Kummer, 1 Sarah Scaglione, 2 Pierre-Henri L. Gaillard, 2 and Kerstin Gari1,4,*

SUMMARY

During DNA replication stress, stalled replication forks need to be stabilized to prevent fork collapse and genome instability. The AAA + ATPase WRNIP1 (Werner Helicase Interacting Protein 1) has been implicated in the protection of stalled replication forks from nucleolytic degradation, but the underlying molecular mechanism has remained unclear. Here we show that WRNIP1 exerts its protective function downstream of fork reversal. Unexpectedly though, WRNIP1 is not part of the well-studied BRCA2-dependent branch of fork protection but seems to protect the junction point of reversed replication forks from SLX4-mediated endonucleolytic degradation, possibly by directly binding to reversed replication forks. This function is specific to the shorter, less abundant, and less conserved variant of WRNIP1. Overall, our data suggest that in the absence of BRCA2 and WRNIP1 different DNA substrates are generated at reversed forks but that nascent strand degradation in both cases depends on the activity of exonucleases and structure-specific endonucleases.

INTRODUCTION

During DNA replication, forks can encounter a plethora of situations that hinder their progression, such as a shortage of nucleotides, unrepaired DNA lesions, torsional stress, DNA secondary structures, transcription complexes, and RNA:DNA hybrids (Zeman and Cimprich, 2014). In response to virtually all such situations of DNA replication stress, stalled replication forks seem to get remodeled into four-way junctions (Zellweger et al., 2015), presumably to stabilize them until the fork-stalling obstacle is cleared (Neelsen and Lopes, 2015). During this process, termed replication fork reversal, DNA translocases, such as ZRANB3, SMARCAL1, and HLTF, drive the reannealing of the two parental DNA strands and the concomitant annealing of the newly synthesized strands to form a four-way junction (Achar et al., 2011, 2015; Bé touss et al., 2012; Ciccia et al., 2012; Kile et al., 2015; Poole and Cortez, 2017; Vujanovic et al., 2017). In addition to these factors, the well-known recombination protein RAD51 is required for the formation of reversed forks (Zellweger et al., 2015), a function that is, in contrast to its role in homologous recombination, independent of its interaction partner BRCA2 (Mijic et al., 2017).

Although replication fork reversal is considered a protective measure, reversed replication forks, when not adequately stabilized, represent a source of genome instability, because they can become entry points for uncontrolled exonucleolytic degradation (Kolinjivadi et al., 2017; Lemaçon et al., 2017; Mijic et al., 2017; Tagliatela et al., 2017). BRCA2 plays an important role in the protection of reversed replication forks, presumably by assembling RAD51 filaments on the 3′-single-stranded (ss) DNA end of the reversed arm (Hashimoto et al., 2010; Mijic et al., 2017; Schlacher et al., 2011). A number of other proteins have been implicated in the protection of stalled replication forks from nucleolytic cleavage, such as BRCA1, FANC D2, REV1, BOD1L (Higgs et al., 2015; Schlacher et al., 2012; Yang et al., 2015), and more recently WRNIP1 (Leuzzi et al., 2016). Their mode of action in this context has however remained elusive, and it is unclear whether they exert their protective role at the level of the stalled or the reversed replication fork.

The AAA + ATPase WRNIP1 had initially been implicated in the maintenance of genome stability because of its physical interactions with DNA replication and repair proteins, such as the eponymous Werner helicase (WRN) and DNA polymerase delta (Kawabe et al., 2001; Tsurimoto et al., 2005). Moreover, it was found to colocalize with the replication fork remodeler ZRANB3 upon PCNA hyperubiquitination (Ciccia et al., 2012) and identified as a replication-associated repair protein enriched on nascent chromatin upon replication stress (Alabert et al., 2014; Dungrawala et al., 2015).

Here we provide evidence that, as BRCA2, WRNIP1 protects stalled replication forks that have undergone fork reversal. In contrast to BRCA2, however, WRNIP1 does not seem to protect the end of the...
protruded arm, but rather the junction point, of the reversed fork. Our data suggest that WRNIP1 may be able to do so by directly binding to reversed replication forks, thereby shielding them from SLX4-mediated cleavage.

**RESULTS**

**WRNIP1 Protects Reversed Replication Forks in a Mechanistically Different Way Than BRCA2**

We first asked whether WRNIP1 was involved in the protection of reversed rather than stalled replication forks, similarly to what was recently reported for BRCA2 (Kolinjivadi et al., 2017; Lemaçon et al., 2017; Mijic et al., 2017; Taglialatela et al., 2017). To do so, we employed a widely used DNA fiber labeling approach in U2OS cells, in which we gave two consecutive pulses of CldU and IdU followed by a 5-h treatment with hydroxyurea to block DNA replication (Figure 1A; Table S1). In agreement with previous data (Leuzzi et al., 2016), in the absence of WRNIP1, nascent strands got degraded, resulting in a reduced IdU/CldU tract length ratio (Figure S1A). This effect could be completely reverted when either of the fork remodelers ZRANB3 or HLTF is codepleted with WRNIP1 (Figures 1B and S1B), suggesting that WRNIP1 acts downstream of fork reversal. Moreover, we also saw a complete restoration of fork stability when RAD51 was depleted on top of WRNIP1 (Figures 1B and S1B). Given RAD51’s essential role in the promotion of fork reversal (Zallaefer et al., 2015), this finding further suggests that WRNIP1, as BRCA2, protects stalled replication forks after they have undergone fork reversal.

![Figure 1](image-url)
Since the inhibition of nucleases that are canonically involved in the processing of double-stranded DNA ends, such as MRE11, CtIP, and EXO1, can alleviate the fork degradation phenotype associated with knock-down of BRCA2 (Lemaçon et al., 2017; Schlacher et al., 2011), it is assumed that BRCA2 protects the protruded reversed arm, presumably by promoting the assembly of a RAD51 filament (Mijic et al., 2017). This notion is consistent with the observation that inhibition of MRE11’s 3’–5’ exonuclease activity by mirin prevented the BRCA2 depletion-associated fork degradation phenotype to the same extent as a complete depletion of MRE11 by RNA interference, whereas the MRE11 endonuclease inhibitor PFM01 only led to a partial restoration of fork stability (Figure 1C, right panel; S1C, and S1D). In surprising contrast, fork degradation upon knock-down of WRNIP1 was prevented by depletion of MRE11 or inhibition of MRE11’s endonuclease activity by PFM01, whereas inhibiting MRE11’s exonuclease activity by mirin had only a very minor rescue effect (Figures 1C, left panel; S1C, and S1D). Our findings hence suggest that, in contrast to what has been proposed previously, WRNIP1’s and BRCA2’s fork protection functions seem to be mechanistically distinct.

WRNIP1 Protects Reversed Replication Forks from SLX4-Mediated Endonucleolytic Cleavage

In light of these observations, we then wondered whether WRNIP1, instead of protecting the protruded arm of a reversed fork, could rather shield its junction point, e.g., from the attack of structure-specific endonucleases. Over the last years, a number of endonucleases that are able to target four-way junctions have been discovered (Déhé and Gaillard, 2017). Several of them, namely SLX1, MUS81-EME1, and XPF-ERCC1, form a multiprotein complex with the scaffold protein SLX4 (Fekairi et al., 2009; Muñoz et al., 2009; Svendsen et al., 2009). In vitro, they have partially overlapping substrate preferences and can influence each other’s biochemical activities (Wyatt et al., 2013, 2017). In vivo, however, they do not seem to form a constitutive complex throughout all cell cycle phases. Notably, cells synchronized in G1/S phase contain a pool of MUS81-EME1 that does not cofractionate with the rest of the complex on a sucrose gradient (Wyatt et al., 2017), suggesting the existence of functional subcomplexes. In addition to being able to cleave recombination-associated Holliday junctions, SLX4 has also been reported to promote endonucleolytic processing of replication forks (for review see Guervilly and Gaillard, 2018). Although this seems to primarily involve MUS81-EME1 and SLX1, SLX4-promoted fork processing by XPF-ERCC1 was recently reported (Béamous et al., 2018).

To assess whether WRNIP1 may be involved in preventing SLX4-driven unscheduled fork processing, we co-depleted WRNIP1 and SLX4 and employed the same fiber labeling approach as described earlier. Depletion of SLX4 completely suppressed the fork degradation phenotype resulting from depletion of WRNIP1 (Figures 2A and S2A), suggesting that in the absence of WRNIP1, reversed forks can become the target of endonucleolytic cleavage. To address which of the SLX4-associated nucleases are involved in fork processing, we then individually co-depleted SLX1, XPF, and MUS81 with WRNIP1. While co-depletion of MUS81 had only a minor effect on fork stability, we could observe a complete alleviation of fork degradation upon co-depletion of XPF and a partial alleviation upon co-depletion of SLX1 (Figures 2A and S2A). These findings fit to previous observations that a major part of MUS81-EME1 is not associated with SLX4 during S phase (Wyatt et al., 2017) and suggest that in the absence of WRNIP1, reversed replication forks may be cleaved by SLX1 and XPF-ERCC1 in an SLX4-dependent manner.

We then wondered whether WRNIP1 could protect reversed replication forks by directly binding to them. To address this possibility, we purified N-terminally Flag-tagged WRNIP1 from Sf9 insect cells (Figure S2B) and tested its ability to bind to a variety of DNA substrates in vitro. Using electrophoretic mobility shift assays (EMSA), we could observe binding of purified WRNIP1 to a DNA structure mimicking a reversed replication fork, whereas it did not show any affinity for single-stranded or double-stranded DNA or for a substrate that resembles a canonical replication fork (Figure 2B). Importantly, WRNIP1’s ability to bind to four-way junction substrates required neither an intact ubiquitin-binding zinc finger (UBZ) domain (Bish and Myers, 2007) nor a functional AAA + ATPase domain (Hishida et al., 2002), because the UBZ domain variant WRNIP1 D37A (Crosetto et al., 2008) and the Walker A and B variants K274A and E329Q were still able to bind to DNA (Figures S2B–S2D).

WRNIP1 Physically and Functionally Interacts with SLX1-SLX4

Given the observed restoration of fork stability upon co-depletion of SLX4 with WRNIP1, and WRNIP1’s ability to bind to four-way junction substrates, we next tested whether WRNIP1 was able to protect a four-way junction substrate from endonucleolytic cleavage in vitro. To do so, we titrated WRNIP1 into a nuclease assay with a four-way junction substrate and purified SLX1-SLX4. With increasing amounts of WRNIP1,
the cleavage product decreased, suggesting that WRNIP1 can indeed protect four-way junctions from SLX1-SLX4 cleavage (Figure 3A). In line with their ability to bind to four-way junction substrates (Figure S2D), a similar effect was also observed when the UBZ or ATPase domain variants were added to SLX1-SLX4 cleavage reactions (Figure S3A).

Strikingly, the protective effect of WRNIP1 seems to be specific for reactions with SLX1-SLX4, because titration of WRNIP1 into a nuclease assay with a nicked four-way junction substrate and purified MUS81-EME1 did not influence MUS81-EME1 cleavage (Figure 3B). Since WRNIP1 has a similar binding affinity for nicked four-way junctions than for intact four-way junctions (Figure S3B), we then wondered whether the observed specificity could stem from a direct interaction between WRNIP1 and SLX1-SLX4. To address this possibility, we immobilized purified SLX1-SLX4 on beads and added purified WRNIP1. In this coimmunoprecipitation experiment we could observe a robust direct interaction between WRNIP1 and the SLX1-SLX4 complex (Figure 3C).

Taken together, our data suggest that WRNIP1 protects the junction point of reversed replication forks from SLX4-dependent endonucleolytic cleavage, presumably through its ability to directly bind to these DNA structures and to interact with SLX1-SLX4. In contrast, WRNIP1 cannot protect from MUS81-EME1 cleavage in vitro, and depletion of MUS81 on top of WRNIP1 does not restore fork stability (Figures 2A and S2A). We further show that the UBZ and ATPase domains of WRNIP1 are dispensable for its protective function in vitro, which is in line with our observation that the UBZ and ATPase domain mutants are able to restore cellular fork stability to a similar extent as the wild-type construct (Figures 3D and S3C).

**Fork Resection in the Absence of Both WRNIP1 and BRCA2 Requires Endonucleolytic and Exonucleolytic Cleavage Steps**

Our data so far suggest that WRNIP1 acts in a different branch of fork protection than BRCA2 by protecting the junction point, rather than the protruded arm, of a reversed fork. Unscheduled SLX4-mediated fork processing alone, however, cannot readily explain the extensive fork degradation phenotype associated with
the depletion of WRNIP1. Since our data show that MRE11’s exonuclease activity is not responsible for long-range fork resection in the absence of WRNIP1 (Figure 1C), we wondered whether the 5′–3′ exonuclease DNA2 that is known to resect unprotected forks upon BOD1L or CtIP depletion (Higgs et al., 2015; Przetocka et al., 2018) could play a role in fork resection upon WRNIP1 knock-down. Indeed, both the depletion of DNA2 and the inhibition of DNA2 by C5 restored fork stability in the absence of WRNIP1, whereas knock-down of the 5′–3′ exonuclease EXO1 had no effect on fork stability (Figures 4A and S4A). In the absence of WRNIP1, SLX4-associated endonucleases may hence target unprotected reversed forks and thereby generate a substrate for extensive DNA2-mediated resection.

These data also underline the difference in fork protection between WRNIP1 and BRCA2, because neither depletion of DNA2 nor use of the DNA2 inhibitor C5 could alleviate the fork degradation phenotype of BRCA2-depleted cells (Lemaçon et al., 2017; Przetocka et al., 2018).

To further delineate these two apparently distinct branches of fork protection, we checked the effect of SLX4 and MUS81 depletion on fork stability in cells lacking BRCA2 (Figures 4B and S4B). If WRNIP1 and BRCA2 were to act independently of each other, also in the absence of BRCA2, WRNIP1 should presumably be able to protect the junction point of a reversed fork from SLX4-dependent cleavage. In agreement with this idea, we observed that fork degradation in BRCA2-depleted cells could not be alleviated by codepletion of SLX4 (Figures 4 and S4B).

On the other hand, codepletion of MUS81 or EME1 with BRCA2 could largely restore fork stability (Figures 4B and S4B). In this context, it should be noted that reversed forks are not a substrate for MUS81-EME1,
which prefers nicked or resected four-way junctions. In the absence of BRCA2, however, MRE11 exonuclease activity may extensively resect reversed replication forks and, hence, convert them into substrates preferred by MUS81-EME1. Given our in vivo (Figure 2A) and in vitro (Figure 3B) data, we would not expect WRNIP1 to be able to protect resected reversed replication forks from MUS81-EME1 cleavage.

Collectively, our data indicate that BRCA2 and WRNIP1 are part of two distinct branches of the fork protection pathway. However, while their loss leads to the generation of different types of DNA structures that are targeted by distinct sets of nucleases, extensive fork resection seems to require, in both cases, an exonucleolytic and endonucleolytic cleavage step.

Only the Short Variant of WRNIP1 Is Able to Bind to DNA and Protect Stalled Replication Forks

In the cell, WRNIP1 transcripts are spliced into two major isoforms that give rise to a 640 amino acid-long protein (used throughout this study and referred to as WRNIP1) and a 665 amino acid-long protein (herein referred to as WRNIP1L), respectively. These two variants differ only by a 25 amino acid-long insertion between the Walker B motif and the ATP-binding arginine finger (Figure 5A). Intriguingly, this insertion is highly conserved, with 84% of amino acid identity between human WRNIP1 and Escherichia coli MgsA, which is clearly above and beyond the, already remarkable, overall conservation (25% of identity) between the human and bacterial protein (Kawabe et al., 2001). Surprisingly, although the large majority of transcripts in the cell encode the long isoform (Figures S5A–S5C), WRNIP1L displayed poor binding to a four-way branched DNA structure (Figures 5B and S5D) and was unable to protect it from SLX1-SLX4-dependent cleavage when titrated into a nuclease assay (Figure 5C).

Making use of this naturally occurring DNA binding-deficient variant we tested our hypothesis that WRNIP1 shields reversed replication forks by directly binding to them. In agreement with this prediction, degradation of replication forks caused by depletion of endogenous WRNIP1 could be prevented by expressing recombinant WRNIP1 but not WRNIP1L (Figure 5D and S5E). Moreover, fork degradation was observed only after the isoform-specific depletion of the short, but not the long, isoform of WRNIP1 (Figures 5D and S5E).

Taken together, these findings indicate that the short, but not the long, variant of WRNIP1 is involved in fork protection from SLX4-mediated cleavage and suggest that WRNIP1’s ability to bind to branched DNA substrates is a prerequisite for this function.

DISCUSSION

In this study, we investigate the molecular mechanism of how WRNIP1 can protect stalled replication forks and find that WRNIP1 exerts its protective function after stalled forks have undergone reversal.

Figure 4. Fork Resection Requires Endonucleolytic and Exonucleolytic Cleavage Steps

(A) Replication fork degradation analysis upon knock-down of WRNIP1 in the absence or presence of the DNA2 inhibitor C5 or upon codepletion of DNA2 or EXO1.

(B) Replication fork degradation analysis upon knock-down of BRCA2 and codepletion of SLX4, MUS81, or EME1. Each dot represents an independent biological replicate. Values and gray bars indicate mean. Statistical analysis: one-way ANOVA with Sidak’s correction for multiple comparisons (****, p < 0.0001; ***, p < 0.001; ns, not significant). Scatterplots of one representative experiment and western blots showing depletion efﬁcacies can be found in Figure S4. CldU, 5-chloro-2’-deoxyuridine; IdU, 5-iodo-2’-deoxyuridine; HU, hydroxyurea; RNAi, RNA interference; si, siRNA.

See also Figure S4 and Tables S1, S3, and S4.
This conclusion is based on our observation that fork stability in WRNIP1-deficient cells is restored upon inactivation of the replication fork remodelers ZRANB3 and HLTF or the recombinase RAD51. It is of note, however, that the latter finding is in conflict with published data that show no alleviation of the WRNIP1 depletion–associated fork degradation phenotype upon knock-down of RAD51 (Leuzzi et al., 2016). In light of RAD51's dual role in the promotion of fork reversal and the protection of reversed forks (Mijic et al., 2017; Zellweger et al., 2015), we suspect that different knock-down efficiencies could be the explanation for the discrepancy between our data and the study by Leuzzi and colleagues. In agreement with this hypothesis, an incomplete knock-down of RAD51 was shown to cause a situation, in which fork reversal is still possible, but RAD51 levels are too low to efficiently protect reversed forks (Bhat et al., 2018). Conversely, a complete knock-down of RAD51 was reported to entirely block fork reversal (Mijic et al., 2017). In the aforementioned WRNIP1 study, a RAD51 inhibitor that selectively prevents RAD51 filament formation was also unable to prevent the WRNIP1 depletion-associated phenotype (Leuzzi et al., 2016). This finding is however not in contradiction with our data, as stable RAD51 filaments are not required for the formation of reversed replication forks (Mijic et al., 2017).
We further show that, even though WRNIP1, as BRCA2, acts downstream of replication fork reversal, the two proteins exert their protective function in different ways. Since mirin, an inhibitor of MRE11’s exonuclease activity, was found to revert the fork degradation phenotype of BRCA2-deficient cells, it was proposed that BRCA2 and RAD51 protect the end of the regressed arm from MRE11 exonuclease-mediated resection (Kolinjivadi et al., 2017; Lemacón et al., 2017; Mijic et al., 2017; Taglialetela et al., 2017). In contrast, we find that mirin has no effect on restoring stalled fork stability in WRNIP1-deficient cells. Instead, we show that depletion of SLX4 or its associated structure-specific endonucleases SLX1 and XPF-ERCC1 restores fork stability in the absence of WRNIP1, suggesting that WRNIP1 protects the junction point of a reversed fork, rather than the end of the protruded arm.

In line with this hypothesis, our in vitro data indicate that WRNIP1 can bind to DNA substrates that mimic reversed replication forks and protect them from endonucleolytic cleavage by SLX1-SLX4. In contrast to a previous study that reported a weak, ATP-dependent binding of WRNIP1 to primer/template junctions and replication fork-like structures (Yoshimura et al., 2009), we did not detect any binding to single- or double-stranded DNA nor replication fork-like structures. Moreover, in our experimental set-up, binding of WRNIP1 to four-way junction substrates was independent of the presence of ATP, and Walker A and B variants of WRNIP1 could bind to four-way junction substrates, and protect them from SLX1-SLX4 cleavage, to a similar extent as the wild-type protein. Accordingly, complementation of WRNIP1-depleted cells with Walker A and B domain mutants could restore fork stability to a similar extent as complementation with a wild-type construct. These findings are also in agreement with a previous study that reports restoration of fork stability with a WRNIP1 variant that has a single amino acid change in between the Walker A and B motifs (T294A) (Leuzzi et al., 2016).

Since protein ubiquitination plays an important role in the context of replication fork reversal (Vujanovic et al., 2017), we also addressed whether WRNIP1’s UBZ domain (Bish and Myers, 2007) was required for its role in fork protection. The UBZ variant D37A WRNIP1 (Crosetto et al., 2008) proved, however, able to bind to DNA substrates in vitro, to protect four-way junctions from SLX1-SLX4 cleavage and to complement WRNIP1-depleted cells to a large extent, suggesting that WRNIP1’s ability to bind to ubiquitin plays at most a minor role in the context of fork protection, possibly to help recruit WRNIP1 more efficiently to sites of DNA replication (Crosetto et al., 2008).

In contrast to what we found in cells lacking WRNIP1, replication fork stability could be restored in BRCA2-depleted cells by knocking-down MUS81 or EME1 but not SLX4. These different genetic interactions may be explained by the distinct substrate selectivity of MUS81-EME1 and SLX1-SLX4. While recombinant SLX1-SLX4 efficiently processes intact four-way junctions, recombinant MUS81-EME1 is much more active on four-way junctions that are nicked or contain one single-stranded arm (Gaillard et al., 2003; Wyatt et al., 2013). We hypothesize that the latter structure could be generated at reversed replication forks in the absence of BRCA2 as a result of MRE11-mediated resection of the protruded arm. Although such a scenario is consistent with a recently published study where MUS81-EME1 was found to drive unscheduled replication fork degradation in BRCA2-deficient cells (Rondinelli et al., 2017), it may not seem consistent at first glance with another recent study that contests a role of BRCA2 in protecting forks from MUS81-mediated cleavage (Lemaçon et al., 2017). It should be noted, however, that in the latter study a modified fiber labeling protocol was employed to exclude forks that are unable to restart after fork resection. Given MUS81’s important role in replication fork restart, as shown in the same study, any restoration of fork stability in the absence of MUS81 could simply not be detected with this approach.

Overall, our data would be in agreement with a model in which WRNIP1 and BRCA2 act in two parallel branches of the fork protection pathway that are both required for the efficient protection of reversed replication forks (Figure 6). We envision that in the absence of WRNIP1, the junction point of a reversed fork would remain unprotected and become a target of SLX4-mediated endonucleolytic cleavage. After SLX4-mediated cleavage, the resulting broken fork could then serve as an entry point for DNA2-mediated nucleolytic degradation that would lead to the extensive nascent DNA degradation that we observe upon WRNIP1 depletion. In contrast, in the absence of BRCA2, the junction point of the reversed fork would initially be protected from SLX4-mediated cleavage by WRNIP1. The MRE11-mediated resection of the unprotected reversed arm, however, would generate a resected reversed fork and, hence, a substrate for MUS81-EME1. In agreement with our in vivo and in vitro
data, WRNIP1 would not be able to prevent MUS81-EME1 cleavage. MUS81-EME1 would therefore be able to incise such a resected reversed fork and, thus, generate an entry point for further MRE11-mediated nucleolytic degradation.

Taken together, we propose that in the absence of BRCA2 and WRNIP1 different DNA substrates are generated at reversed forks but that the extensive nascent strand degradation in both cases depends on the activity of exonucleases and structure-specific endonucleases. This model would imply that in the absence of WRNIP1 and BRCA2 the endpoint of fork degradation is similar, although WRNIP1 and BRCA2 are situated in two distinct branches of the fork protection pathway and protect replication forks in a mechanistically distinct manner. Accordingly, a previous study and our own data (not shown) demonstrate that codepletion of WRNIP1 and BRCA2 does not lead to an additive effect with respect to fork degradation (Leuzzi et al., 2016).

Interestingly, the long isoform of WRNIP1, WRNIP1L, which has a remarkably conserved 25 amino acid-long insertion in the ATPase domain, is unable to bind to DNA and protect it from SLX1-SLX4 cleavage. Moreover, fork stability in WRNIP1-depleted cells cannot be restored by WRNIP1L, suggesting that although WRNIP1L is the prevalent isoform in the cell, it is not the isoform that plays a role in fork protection. It remains to be seen whether, from an evolutionary point of view, the fork protection function of WRNIP1 is a new acquisition or whether in other species this highly conserved region does not interfere with WRNIP1’s ability to protect replication forks. It is of note that WRNIP1 seems to be a moonlighting protein that, in addition to its function in the maintenance of genome stability, also plays a role in antiviral signaling of double-stranded RNA (Tan et al., 2017). Interestingly, in the cited study the long isoform was used to complement WRNIP1 knock-out cells, raising the possibility that the two isoforms could have entirely separate functions with WRNIP1 playing a role in fork protection and WRNIP1L having a function in innate antiviral immunity.

Figure 6. Model Illustrating the Two Branches of Fork Protection That Are Dependent on BRCA2 and WRNIP1, Respectively
See Discussion for details.
Limitations of the Study

Based on our DNA fibers analyses and in vitro experiments, which suggest that the junction point of a reversed fork becomes a target of SLX4-mediated endonucleolytic cleavage in the absence of WRNIP1, we propose a direct role for WRNIP1 in the protection of reversed replication forks.

One prediction of our model would be the formation of double-strand breaks at stalled replication forks in the absence of WRNIP1. Unexpectedly, however, we were not able to detect a significant increase in double-strand breaks upon WRNIP1 depletion, possibly because breaks are formed very transiently, and steady-state levels are therefore very low. More sensitive methods will have to be used in the future to address this issue.

It should also be stressed that DNA fiber assays have an intrinsically low resolution and can therefore only provide an endpoint result. In order to delineate the exact series of nucleolytic events taking place at the site of a stalled replication fork, additional approaches, such as the visualization of replication forks by electron microscopy, will be required to unravel further mechanistic details.

METHODS

All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.10.010.

ACKNOWLEDGMENTS

We are grateful to Lumir Krejci for the kind gift of purified MUS81-EME1, and we thank the whole Gari lab for helpful discussions. This project has received funding from the Swiss National Science Foundation (PP00P3_144784/1 and PP00P3_172959/1), the Human Frontier Science Program (CDA00043/2013-C), the Novartis Foundation for Medical-Biochemical Research (16A047), the “Stiftung für wissenschaftliche Forschung an der Universität Zürich”, and the University of Zurich. Work in the laboratory of P.H.L.G. was supported by an Institut National du Cancer, France PLBIO 2016-159 grant.

AUTHOR CONTRIBUTIONS

B.P. and K.G. conceived the project and designed experiments. B.P., S.W., and S.K. performed experiments. S.S. and P.H.L.G. provided essential reagents and conceptual input. B.P. and K.G. analyzed and interpreted data, prepared figures, and wrote the manuscript with input from P.H.L.G. All authors read and edited the manuscript. K.G. supervised the study.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

Achar, Y.J., Balogh, D., and Haracska, L. (2011). Coordinated protein and DNA remodeling by human HLTF on stalled replication fork. Proc. Natl. Acad. Sci. U S A 108, 14073–14078.

Achar, Y.J., Balogh, D., Neculai, D., Juhasz, S., Morocz, M., Gali, H., Dhe-Paganon, S., Venclovas, C., and Haracska, L. (2015). Human HLTF mediates postreplication repair by its HIRAN domain-dependent replication fork remodelling. Nucleic Acids Res. 43, 10277–10291.

Alabert, C., Bukowski-Wills, J.C., Lee, S.B., Kustatscher, G., Nakamura, K., De Lima Alves, F., Menard, P., Mejriang, J., Rappaport, J., and Groth, A. (2014). Nascent chromatin capture proteomics determines chromatin dynamics during DNA replication and identifies unknown fork components. Nat. Cell Biol. 16, 281–291.

Bérous, R., Mason, A.C., Rambo, R.P., Barsbach, C.E., Badru-Nkinsah, A., Sirbu, B.M., Eichman, B.F., and Cortez, D. (2012). SMARCAL1 catalyzes fork regression and Holliday junction migration to maintain genome stability during DNA replication. Genes Dev. 26, 151–162.

Bérous, R., Goullet de Rugy, T., Pelegrini, A.L., Quelle, S., de Villartay, J.P., and Hoffmann, J.S. (2018). DNA replication stress triggers rapid DNA replication fork breakage by Artemis and XPF. PLoS Genet. 14, e1007541.

Bhat, K.P., Krishnamoorthy, A., Dungrawala, H., Garcin, E.B., Modesti, M., and Cortez, D. (2018). RADX modulates RAD51 activity to control replication fork protection. Cell Rep. 24, 538–545.
Bash, R.A., and Myers, M.P. (2007). Werner helicase-interacting protein 1 binds polyubiquitin via its zinc finger domain. J. Biol. Chem. 282, 23184–23193.

Ciccia, A., Nimonkar, A.V., Hu, Y., Hadju, I., Achar, Y.J., Ilhar, L., Petit, S.A., Adamson, B., Yoon, J.C., Kowalczykowski, S.C., et al. (2012). Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress. Mol. Cell. 47, 396–409.

Crosetto, N., Bienko, M., Hibbert, R.G., Perica, T., Ambrogio, C., Kersche, T., Hofmann, K., Sxiama, T.K., and Dölk, I. (2008). Human Wnsp1 is localized in replication factories in a ubiquitin-binding zinc finger-dependent manner. J. Biol. Chem. 283, 35173–35185.

Dehé, P.M., and Gaillard, P.H.L. (2017). Control of structure-specific endonucleases to maintain genome stability. Nat. Rev. Mol. Cell Biol. 18, 315–330.

Dungawala, H., Rose, K.L., Bhat, K.P., Mohi, K.N., Glick, G.G., Couch, F.B., and Cortez, D. (2018). The replication checkpoint prevents two types of fork collapse without regulating replisome stability. Mol. Cell. 79, 998–1010.

Fekairi, S., Scaglione, S., Chawhan, C., Taylor, E.R., Tissier, A., Coulson, S., Dong, M.Q., Ruse, C., Yates, J.R., Russell, P., et al. (2009). Human SLX4 is a holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell 138, 78–89.

Gaillard, P.H.L., Noguchi, E., Shanahan, P., and Russell, P. (2003). The endogenous Mus81-Eme1 complex resolves Holliday junctions by a nick and resolution translocase to maintain genomic Integrity after replication stress. EMBO J. 33, 1437–1451.

Mijic, S., Zellweger, R., Chappidi, N., Berti, M., Jacobs, K., Mutreja, K., Uirsch, S., Ray Chaudhuri, A., Nussenzweig, A., Janscak, P., et al. (2017). Repair fork reversion triggers fork degradation in BRCA2-defective cells. Nat. Commun. 8, 859.

Muñoz, I.M., Hain, K., Déclais, A.C., Gardiner, M., Toh, G.W., Sanchez-Pulido, L., Heuckmann, J.M., Toth, R., Macartney, T., Eppink, B., et al. (2009). Coordination of structure-specific nucleases by human SLX4/BTBD12 is required for DNA repair. Mol. Cell 35, 116–127.

Neelsen, K.J., and Lopes, M. (2015). Replication fork reversion in eukaryotes: from dead end to dynamic response. Nat. Rev. Mol. Cell Biol. 16, 207–220.

Poole, L.A., and Cortez, D. (2017). Functions of SMARCAL1, ZRANB3, and HLTF in maintaining genome stability. Nat. Rev. Mol. Cell Biol. 18, 696–714.

Przetocka, S., Porro, A., Bolck, H.A., Walker, C., Lezaja, A., Trenner, A., van Aesch, C., Himmels, S.F., D’Andrea, A.D., Ceccaldi, R., et al. (2018). CtIP-mediated fork protection synergizes with BRCA1 to suppress genomic instability upon DNA replication stress. Mol. Cell 72, 568–582.e6.

Rondinelli, B., Gogola, E., Yücel, H., Duarte, A.A., Van De Ven, M., Van Der Sluijs, J., Konstantinopoulos, P.A., Jonkers, J., Ceccaldi, R., Rottenberg, S., et al. (2017). EZH2 promotes degradation of stalled replication fork by recruiting MUS81 through histone H3 tri-methylation. Nat. Cell Biol. 19, 1371–1378.

Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., and Jasin, M. (2011). Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 145, 529–542.

Schlacher, K., Wu, H., and Jasin, M. (2012). A distinct replication fork protection pathway connects fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 22, 106–116.

Swendsen, J.M., Smogorzewska, A., Sowa, M.E., O’Connell, B.G., Gygi, S.P., Eldridge, S.J., and Harper, J.W. (2009). Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 138, 63–77.

Taglialatela, A., Alvarez, S., Leuzig, G., Sannino, V., Ranjha, L., Huang, J.W., Madubata, C., Anand, R., Lesy, B., Rabadian, R., et al. (2017). Restoration of replication fork stability in BRCA1- and BRCA2-deficient cells by inactivation of SFN2-family fork remodelers. Mol. Cell 68, 414–430.e8.

Tan, P., He, L., Cui, J., Qian, C., Cao, X., Lin, M., Zhu, Q., Li, Y., Xing, C., Yu, X., et al. (2017). Assembly of the WHIP-TRIM14-PPP6C mitochondrial complex promotes RIG-I-mediated antiviral signaling. Mol. Cell 68, 293–305.e7.

Tsurimoto, T., Shinozaki, A., Yano, M., Seki, M., and Enomoto, T. (2005). Human Werner helicase interacting protein 1 (WRNIP1) functions as novel modulator for DNA polymerase 6. Genes Cells 10, 13–22.

Vujanovic, M., Kretsch, J., Raso, M.C., Terraneo, N., Zellweger, R., Schmid, J.A., Taglialatela, A., Huang, J.W., Holland, C.L., Zwicky, K., et al. (2017). Replication fork slowing and reversal upon DNA damage require PCNA polyubiquitination and ZRANB3 DNA translocase activity. Mol. Cell 67, 882–890.e5.

Wyatt, H.D.M., Sarbajna, S., Matos, J., and West, S.C. (2013). Coordinated actions of SLX1-SLX4 and MUS81-EME1 for holliday junction resolution in human cells. Mol. Cell 52, 234–247.

Wyatt, H.D.M., Laister, R.C., Martin, S.R., Arowosum, C.H., and West, S.C. (2017). The SMX DNA repair tri-nuclease. Mol. Cell 65, 848–860.e11.

Yang, Y., Liu, Z., Wang, F., Temvriyanukul, P., Ma, X., Tu, Y., Lu, L., Lin, Y.F., Huang, M., Zhang, T., et al. (2015). FANCD2 and REV1 cooperate in the protection of nascent DNA strands in response to replication stress. Nucleic Acids Res. 43, 8325–8339.

Yoshimura, A., Seki, M., Kanamori, M., Tateishi, S., Tsurimoto, T., Tada, S., and Enomoto, T. (2009). Physical and functional interaction between WRNIP1 and RAD18. Genes. Genet. Syst. 84, 171–178.

Zellweger, R., Dalcher, D., Mutreja, K., Berti, M., Schmid, J.A., Herrador, R., Vindigni, A., and Lopes, M. (2015). Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells. J. Cell Biol. 208, 563–579.

Zeman, M.K., and Cimprich, K.A. (2014). Causes and consequences of replication stress. Nat. Cell Biol. 16, 2–9.
Supplemental Information

WRNIP1 Protects Reversed DNA Replication Forks from SLX4-Dependent Nucleolytic Cleavage

Bartłomiej Porebski, Sebastian Wild, Sandra Kummer, Sarah Scaglione, Pierre-Henri L. Gaillard, and Kerstin Gari
Figure S1. WRNIP1 protects reversed replication forks in a different way than BRCA2, Related to Figure 1. (A) Left: Replication fork degradation analysis in cells depleted of WRNIP1 using different siRNA sequences. Each dot represents an independent biological replicate. Values and grey bars indicate mean. Statistical analysis: one-way ANOVA with Sidak’s correction for multiple comparisons. Middle: scatter plot of one representative experiment. Each dot represents one replication fork. Values and red bars indicate median. Statistical analysis: Kruskal-Wallis test. Right: western blots. (B) Replication fork degradation analysis upon knock-down of WRNIP1 and co-depletion of factors involved in replication fork reversal. Left: scatter plot of one representative experiment. Each dot represents one replication fork. Values and red bars indicate median. Statistical analysis: Kruskal-Wallis test. Right: western blots. (C) Replication fork degradation analysis upon knock-down of WRNIP1 (left) or BRCA2 (right) in the absence or presence of the MRE11 exonuclease inhibitor mirin, the MRE11 endonuclease inhibitor PFM01 or upon co-depletion of MRE11. Left: scatter plots of one representative experiment. Each dot represents one replication fork. Values and red bars indicate median. Statistical analysis: Kruskal-Wallis test. Right: western blots. (D) Replication fork degradation analysis in cells depleted of indicated nucleases or treated with indicated inhibitors. Each dot represents one replication fork. Values and grey bars indicate median. Statistical analysis: Kruskal-Wallis test. si, siRNA; WB, western blot; p values (****, $p < 0.0001$; ***, $p < 0.001$; **, $p < 0.01$; *, $p < 0.1$; ns, not significant).
Figure S2. WRNIP1 protects reversed replication forks from SLX4-dependent nucleolytic cleavage, Related to Figure 2. (A) Replication fork degradation analysis upon knock-down of WRNIP1 and co-depletion of SLX4 and associated nucleases. Top: scatter plots of one representative experiment. Each dot represents one replication fork. Values and red bars indicate median. Statistical analysis: Kruskal-Wallis test. Bottom: western blots. (B) InstantBlue-stained SDS gels of purified Flag-WRNIP1 variants. (C) ATPase activity of wild-type WRNIP1 and the Walker A and B variants K274A and E329Q in the absence of DNA (–) or in the presence of ssDNA (ss), dsDNA (ds) or a four-way junction substrate (4WJ), as measured by release of inorganic phosphate (Pi) from radio-labelled γ-32P-ATP in thin-layer chromatography. Error bars depict standard deviation from three independent experiments. (D) EMSA showing WRNIP1 variants' ability to bind to a four-way junction substrate. si, siRNA; WB, western blot; p values (****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.1; ns, not significant).
Figure S3. ATP- and ubiquitin binding are largely dispensable for WRNIP1’s role at stalled DNA replication forks, Related to Figure 3. (A) Endonucleolytic cleavage assay of SLX1-SLX4 in the presence of increasing amounts of WRNIP1 variants. (B) EMSA showing binding of wild-type WRNIP1 to an intact four-way junction substrate (left) and a nicked four-way junction substrate (right). (C) Replication fork degradation analysis in WRNIP1-depleted cells, complemented with WRNIP1 variants. Endogenous WRNIP1 was depleted by siRNA targeting the 3´-UTR. Left: scatter plot of one representative experiment. Each dot represents one replication fork. Values and red bars indicate median. Statistical analysis: Kruskal-Wallis test. Right: western blots. si, siRNA; WB, western blot; p values (***, p < 0.001; **, p < 0.01; *, p < 0.1; ns, not significant).
Figure S4. Fork resection requires endonucleolytic and exonucleolytic cleavage steps, Related to Figure 4. (A) Replication fork degradation analysis upon knock-down of WRNIP1 in the absence or presence of the DNA2 inhibitor C5 or upon co-depletion of DNA2 or EXO1. Left: scatter plots of one representative experiment. Each dot represents one replication fork. Values and red bars indicate median. Statistical analysis: Kruskal-Wallis test. Right: western blots. (B) Replication fork degradation analysis upon knock-down of BRCA2 and co-depletion of SLX4, MUS81 or EME1. Left: scatter plots of one representative experiment. Each dot represents one replication fork. Values and red bars indicate median. Statistical analysis: Kruskal-Wallis test. Right: western blots. Please note that the left half of the upper western blot of Figure S4B is identical to the left half of the left western blot in Figure S2A, since the experiments were done in parallel and the control samples used were the same. si, siRNA; WB, western blot; p values (****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.1; ns, not significant).
Figure S5. WRNIP1, but not WRNIP1L, can protect reversed replication forks, Related to Figure 5.
(A) End-point RT PCR-based analysis of isoform abundance of WRNIP1/WRNIP1L in U2OS cells. Upper panel depicts the analysed locus. Lower panel shows electrophoretic analysis of the end-point PCR reaction on a cDNA library. (B) Western blot showing comparison of ectopically expressed untagged WRNIP1 isoforms to endogenous WRNIP1 from U2OS, RPE-1 and HEK 293T cell lines. (C) Expression levels of WRNIP1 isoforms in different tissues. Graph was generated using the ISOexpresso tool that utilises TCGA database. (D) InstantBlue-stained SDS gel of purified wild-type WRNIP1L. (E) Replication fork degradation analysis upon knock-down of WRNIP1 and complementation with cDNAs expressing the short (WRNIP1) or long (WRNIP1L) isoform (left panels). Right panels, knock-down of WRNIP1 (short isoform) or WRNIP1L (long isoform) using isoform-specific siRNAs. Top: scatter plots of one representative experiment. Each dot represents one replication fork. Values and red bars indicate median. Statistical analysis: Kruskal-Wallis test. Bottom: western blots. si, siRNA; WB, western blot; p values (****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.1; ns, not significant).
Table S2. Oligos used in this study, Related to Figures 2, 3 and 5.

| name    | sequence (5´–3´)                                                                 |
|---------|---------------------------------------------------------------------------------|
| X01     | GACGCTGCCGAATTCTACCAGTGCTTAGGACATCTTTGCCCACCTGCAGGTTCCACC                      |
| X01c    | GGGAACGTGCAGGGAAGATAGTCTAGCAAGGACTGGAATTGCAGGGACGCAGTC                         |
| X02     | TGGGTGAACCTGCAGGTGGCAAAGATGTCCTGTAAGCTCAGACGCGACGCAGTC                         |
| X02.1/2 | TGGGTGAACCTGCAGGTGGCAAAGATGTCCTGTAAGCTCAGACGCGACGCAGTC                         |
| X03     | GAACGGCATAAGCCTGACGATTACAAACAGACTGGAAGCTGCTAGAGAGAGATGCCGACTATCGA              |
| X03.1/2 | CATGGAGCTGTCTAGAGAATCCGACTATCGA                                               |
| X03.1/2_2 | GAACGGCATAAGCCTGACGATTACAAACAGAT                                             |
| X04     | ATCGATAGTCGGATCCTTAGACGCTGCTCAGCAAGGACTGGTAGAATTTCGGCAGCGT                      |
Table S3. siRNAs used in this study, Related to Figures 1-5.

| name          | target gene | target region     | reference                              | sequence (5’-3’)                        |
|---------------|-------------|-------------------|----------------------------------------|-----------------------------------------|
| siControl     | –           | –                 | Microsynth (neg. control)              | AGG UAG UGU AAU CGC CUU G               |
| siBRCA2       | BRCA2       | BRCA2 mRNA: 3401-3421 | (Mijic et al., 2017)                   | AAC UGA GCA AGC CUC ACU CAA            |
| siHLTF        | HLTF        | HLTF mRNA: 567-585 | (Blastyak et al., 2010)                | GGU GCU UUG GCC UAU AUC A               |
| siMRE11 #1    | MRE11       | MRE11 mRNA: 2436-2454 | this study                            | GAG CAU AAC UCC AUA AGU A              |
| siMRE11 #2    | MRE11       | MRE11 mRNA: 1793-1811 | (Yuan and Chen, 2010)                 | GGA GGU ACG UCG UU CAG A               |
| siMUS81       | MUS81       | MUS81 mRNA: 1825-1843 | (Di Marco et al., 2017)               | CAG CCC UGG UGG AUC GAU A              |
| siRAD51       | RAD51       | RAD51 mRNA: 1327-1345 | (Mijic et al., 2017)                  | GAC UGC CAG GAU AAA GCU U              |
| siSLX1        | SLX1        | SLX1 mRNA: 1047-1067 | (Muñoz et al., 2009)                  | UGG ACA GAC CUG CUG GAG AUU            |
| siSLX4 #1     | SLX4        | SLX4 mRNA: 5826-5848 | (Mutreja et al., 2018)                | CCG CAU UUG AGU CUG CAG GUG AA         |
| siSLX4 #2     | SLX4        | SLX4 mRNA: 3181-3201 | (Mutreja et al., 2018)                | AAA CGU GAA UGA AGC AGA AUU            |
| siWRNIP1 #1   | WRNIP1      | WRNIP1 mRNA: 1099-1117 | this study                           | CAA CAA AUG CCA AGA CAA A              |
| siWRNIP1 #2   | WRNIP1      | WRNIP1 mRNA: 1639-1657 | this study                           | CAG AGA AUG ACG UGA AGG A              |
| siWRNIP1 #3   | WRNIP1      | WRNIP1 mRNA: 2301-2319 (3' UTR) | this study | UUA GAA CAG ACC AAC AUU U |
| siWRNIP1L     | WRNIP1 (long isoform) | 2-20 nt of the insertion | this study                           | ACA CUU UCC UUC CUC ACG U              |
| siWRNIP1S     | WRNIP1 (short isoform) | -4 to +14 around the insertion site | this study                           | CAG GUC AAC GCU GCU CUC C              |
| siZRANB3      | ZRANB3      | ZRANB3 mRNA: 2127-2145 | this study                           | UCA GAA AGA CAC CUC CAA A              |
| siXPF         | XPF         | XPF mRNA: 341-359  | (Mutreja et al., 2018)                | GUA GGA UAC UUG UGG UUG A              |
| siDNA2        | DNA2        | DNA2 mRNA: 3267-3285 | (Thangavel et al., 2015)              | CAG UAU CUC CUC UAG CUG A              |
| siEME1        | EME1        | EME1 mRNA: 328-345  | (Pepe and West, 2014)                 | GCU AAG CAG UGA AAG UGA A              |
| siEXO1        | EXO1        | EXO1 mRNA: 2243-2261 | (Przetocka et al., 2018)              | GCC UGA GAA UAA UAU GUC U              |

Note that siWRNIP1 #3 was used in all experiments and is referred to as “siWRNIP1”. 
Table S4. Antibodies used in this study, Related to Figures 1-5.

| antibodies      | manufacturer               | catalogue number | source   | use     | dilution |
|-----------------|-----------------------------|------------------|----------|---------|----------|
| **primary antibodies** |                             |                  |          |         |          |
| WRNIP1 G-2      | Santa-Cruz Biotechnology    | sc-377402        | mouse    | WB      | 1:1000   |
| WRNIP1 N-17     | Santa-Cruz Biotechnology    | sc-55437         | goat     | WB      | 1:1000   |
| Flag M2         | Sigma-Aldrich               | F1804            | mouse    | WB      | 1:1000   |
| His             | GE Healthcare               | 27-4710-01       | mouse    | WB/IP   | 1:1000   |
| HLTF            | GeneTex                     | GTX114776        | rabbit   | WB      | 1:1000   |
| ZRANB3          | ProteinTech                 | 23111-1-AP       | rabbit   | WB      | 1:1000   |
| RAD51           | Santa-Cruz Biotechnology    | sc-8349          | rabbit   | WB      | 1:1000   |
| MRE11           | Novus Biological            | NB100-142        | rabbit   | WB      | 1:1000   |
| BRCA2           | EMD Millipore               | OP95             | mouse    | WB      | 1:1000   |
| SLX4            | Bethyl Laboratories         | A302-270A        | rabbit   | WB      | 1:1000   |
| MUS81           | Sigma-Aldrich               | M1445            | mouse    | WB      | 1:1000   |
| XPF             | Bethyl Laboratories         | A301-315A        | rabbit   | WB      | 1:1000   |
| DNA2            | Abcam                       | ab96488          | rabbit   | WB      | 1:1000   |
| EME1            | Santa-Cruz Biotechnology    | sc-53275         | mouse    | WB      | 1:1000   |
| EXO1            | Bethyl Laboratories         | A302-640A        | rabbit   | WB      | 1:1000   |
| Actin           | Santa-Cruz Biotechnology    | sc-47778         | mouse    | WB      | 1:2000   |
| Tubulin         | Santa-Cruz Biotechnology    | sc-9104          | mouse    | WB      | 1:1000   |
| BrdU/CldU       | Abcam                       | ab6326           | rat      | DNA fibres | 1:500   |
| BrdU/IdU        | Becton Dickinson            | 347580           | mouse    | DNA fibres | 1:80    |
| **secondary antibodies** |                             |                  |          |         |          |
| anti-Mouse-HRP  | Amersham                    | NA931            | sheep    | WB      | 1:5000   |
| anti-Rabbit-HRP | Amersham                    | NA934            | donkey   | WB      | 1:5000   |
| anti-Goat-HRP   | Santa-Cruz Biotechnology    | sc-2354          | mouse    | WB      | 1:5000   |
| anti-Mouse-Alexa488 | Invitrogen                | A-11029          | goat     | DNA fibres | 1:300   |
| anti-Rat-Cy3    | Jackson ImmunoResearch      | 712-165-153      | donkey   | DNA fibres | 1:300   |
Transparent Methods

Plasmids and baculoviruses
WRNIP1 cDNA was purchased from Mammalian Gene Collection (Dharmacon) as a bacterial stab. The cDNA was cloned into pDONR221™ GATEWAY® entry vector (Invitrogen) according to the manufacturer’s protocol and transformed into competent bacteria. WRNIP1L was cloned by a series of PCR reactions using WRNIP1-pDONR221 as a template. All entry vectors were analysed by restriction digest reactions and sequencing (Microsynth). GATEWAY® destination vectors were generated according to the manufacturer’s protocol. Site-directed mutagenesis was performed according to the original idea of Stratagene (QuikChange® Site-Directed Mutagenesis, Stratagene) on GATEWAY® entry vectors. Bacmids and baculoviruses were generated using the Bac-to-Bac® Baculovirus Expression System (Invitrogen) approach.

Protein purifications
All human WRNIP1 variants were purified from Sf9 insect cells. A liquid culture at a density of 2x10^6 cells/ml was infected with baculoviruses at an MOI = 1. Cells were incubated with shaking at 25 °C for 48 hours, and harvested and lysed in 5 PCV (packed-cell volume) of Lysis Buffer (50 mM Na-phosphate pH 7.0, 150 mM NaCl, 10% glycerol, 0.1% NP-40, 1 mM TCEP, 0.5 mM EDTA), supplied with protease inhibitors cocktail (Roche) for 30 minutes on ice with intermittent vortexing. Lysates were spun down at 4 °C in a Sorvall™ WX+ (Thermo Scientific) ultracentrifuge equipped with a T-865 rotor at 37,500 rpm for 1 hour. Supernatant was collected and filtered through 0.45 μm and 0.22 μm filters. Resulting cell lysates were incubated with 0.01 volumes of equilibrated Flag M2 beads (Sigma Aldrich) for 2 hours at 4 °C with rotation. Afterwards, beads were washed 3 times for 10 minutes in 10 ml of the Lysis Buffer at 4 °C with rotation, followed by 3 washes with Storage Buffer (Lysis Buffer minus EDTA). Afterwards, bound proteins were eluted twice with 5 beads volumes of the Storage Buffer supplemented with 200 ng/μl 3x FLAG® peptide (Sigma) for 1 hour at 4 °C, with rotation. Flag-IP eluates were filtered on 0.22 μm spin columns (Bio-Rad), aliquoted, snap-frozen and stored at -80 °C. Concentration was estimated from quantification of SDS-PAGE, followed by calculations based on a BSA standard curve.

Human SLX1-SLX4 was purified from bacteria as a complex of His-tagged full-length SLX1 and the His-tagged CCD domain of SLX4, as described previously (Fekairi et al., 2009). MUS81-EME1 was purified from bacteria, as described previously (Di Marco et al., 2017).

DNA substrates
All oligonucleotides used for DNA substrate preparation were synthesised by Microsynth and are listed in Table S2. Oligonucleotide X01 served as a basis for all substrates used in this study and was therefore labelled on the 5’-end by fluorescein amidite during synthesis. Annealing of DNA substrates was done in a buffer containing 10 mM Tris-HCl pH 8.0, 50 mM NaCl and 10 mM MgCl2. Oligonucleotides were mixed, incubated for 5 minutes at 95 °C and then allowed to cool down to room temperature.

DNA substrates were composed of the following oligonucleotides:

- ssDNA: X01
- dsDNA: X01, X01c
- replication fork: X01, X02.1/2, X03.1/2, X04
- 4-way junction: X01, X02, X03, X04
- nicked 4-way junction: X01, X02, X03.1/2, X03.1/2_2, X04
DNA binding
DNA binding was done in 10 μl reactions containing 1 μl of DNA substrate (final concentration: 5 nM) and 9 μl of protein dilution. Reactions were incubated on ice for 20 minutes, followed by addition of loading buffer (final: 3.5% Ficoll, 10 mM Tris-Cl pH 7.5, 10 mM EDTA, Xylene cyanol) and analysis by native gel electrophoresis using 0.5X TBE 6% polyacrylamide gels at room temperature. The gels were scanned using a Typhoon™ FLA9500 (GE Healthcare) scanner.

ATPase activity
ATPase activity was measured in 5 μl reactions containing 5 mM MgCl₂, 0.01 mM ATP, 0.033 μM ATP-γ-³²P, 23.5 nM of protein and, optionally, 50 nM of a DNA substrate. Reactions were incubated at 37 °C for 30 minutes and then stopped by addition of EDTA to a final concentration of 50 mM. 1 μl of the sample was spotted on a PEI-Cellulose thin-layer chromatography plate (Merck), and the plates were resolved in a solution containing 0.15 M LiCl and 0.15 M formic acid. Resolved plates were air-dried, wrapped in cling film and analysed by autoradiography.

In vitro four-way junction protection
The reversed fork protection assay was done by titrating WRNIP1 into SLX1-SLX4 nuclease reactions. WRNIP1 was first pre-incubated with the DNA substrate (4 μl of WRNIP1 dilution, 1 μl of 50 nM DNA) for 10 minutes on ice. Then a 5 μl mix of SLX1-SLX4 in SLX reaction buffer was added to have a final concentration of 25 mM Tris-HCl pH 7.5, 0.25 mM β-mercaptoethanol, 50 μg/ml BSA (New England Biolabs), and 0.5 mM MgCl₂. Reactions were carried out at 37 °C for 10 minutes, deproteinised for 10 minutes at 37 °C with 2 mg/ml Proteinase K and 0.4% SDS and resolved by native PAGE through 8% polyacrylamide gels in 1x TBE. Gels were scanned using Typhoon™ FLA9500 (GE Healthcare) scanner.

Reversed fork protection assays with MUS81-EME1 were essentially done the same, except that the ME1 reaction buffer was chosen such that the final reactions contained 25 mM Tris-HCl (pH 7.5), 2.5 mM MgCl₂ and 20 mM KCl.

Co-IPs
The purified complex of His-tagged full-length SLX1 and the His-tagged CCD domain of SLX4 was pre-incubated with Flag-tagged WRNIP1 in lysis buffer for 1h at 4°C. In the meantime, anti-His antibodies were bound to Protein G Sepharose Fast Flow beads (Sigma Aldrich) for 2h at 4°C. The SLX1-SLX4/WRNIP1 binding mix (or the control mix containing WRNIP1 only) was then added to the beads and incubated overnight at 4°C. Beads were then washed extensively in lysis buffer and boiled in 2x sample buffer. Bound proteins were analysed by western blotting.

Mammalian cell culture
All human cell lines were grown in DMEM (Dulbecco’s Modified Eagle Medium, Gibco) supplied with 10% fetal bovine serum (Gibco) at 37 °C and 5% oxygen. For replicates of phenotypical analyses, cells of similar passage number were used (±2) to ensure reproducibility of conditions. Sf9 insect cells were grown in HyClone™ SFX-Insect™ cell culture media (GE Healthcare) at 25 °C with shaking.

Plasmid transfections
Transfection of bacmids to Sf9 insect cells was done using TransIT®-LT1 Transfection Reagent (Mirus) according to the manufacturer’s protocol. Human U2OS cells were transfected using jetPRIME® (Polypeptide-transfection®) according to the manufacturer’s protocol (10 μg plasmid DNA per ø10 cm culture dish; 1:3 (w/v) DNA:jetPRIME® ratio); medium was replaced after 6-8 hours.

RNA interference
Short interfering RNA duplexes were designed using Sfold (http://sfold.wadsworth.org/), unless otherwise stated, and synthesised at Microsynth. U2OS cells were transfected with siRNAs using
DharmaFECT1 Tranfection Reagent (Dharmacon). Tranfection mix equal to 1:10 of culture medium volume was prepared in Opti-MEM™ (Gibco) by mixing siRNA (final 40 nM) with the transfection reagent (0.55 μl per 100 μl of the mix, irrespective of number of siRNAs used); the mixture was incubated at RT for 10 minutes and added to the cells. The growth medium was replaced after 24 hours. Sequences of siRNAs used in the study are listed in Table S3.

**Cell extracts**

Unless otherwise stated, human and insect cells were lysed by incubating PBS-washed cell pellets with 5 PCV (packed-cell volume) of Lysis Buffer (50 mM Na-phosphate pH 7.0, 150 mM NaCl, 10% glycerol, 0.1% NP-40, 1 mM TCEP, 0.5 mM EDTA), supplied with protease inhibitors cocktail (Roche) and, optionally, 0.1% Benzonase® (Sigma) or PhosSTOP™ (Roche), for 30 minutes on ice with intermittent vortexing. Next, lysates were spun down at 17,200 x g for 30 minutes at 4 °C; supernatants were collected. If needed, concentrations of the lysates were analysed using Bradford assay and normalised.

**Western blotting**

For protein analysis by western blotting, samples were boiled in Laemmli sample buffer and separated by SDS-PAGE run at 180 V for 1 h or 100 V for 2 h. Proteins were then transferred onto nitrocellulose or PVDF membranes at 100 V for 1-2 hours in the cold. Afterwards, membranes were blocked in 5% milk-TBST (Tris-buffered saline supplemented with 0.01% Tween®20) solution for 30 minutes and incubated with primary antibody solution overnight at 4 °C. Then, membranes were briefly washed with TBST and incubated with appropriate secondary antibody (1:5000) for 2 hours at RT. The membranes were then washed several times with TBST and the signal was developed using Clarity™ Western ECL Blotting Substrate (Bio-Rad) or SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Scientific).

Primary and secondary antibodies used in this study are listed in Table S4.

**DNA fibre analysis**

DNA fibre analysis was carried out following a previously published protocol (Jackson and Pombo, 1998). Prior to the analysis of DNA fibres, cells were seeded in 12-well plates at a density which ensured that the cultures were 70-80% confluent at the day of labelling. Immediately before labelling, cells were washed 3 times with pre-warmed PBS (phosphate-buffered saline). Next, cells were incubated with DMEM containing 0.04 mM CldU (5-Chloro-2’deoxyuridine, Sigma), followed by washing with pre-warmed PBS (3 times, brief). Subsequently, cells were incubated with DMEM containing 0.34 mM IdU (5’-Iodo-2’deoxyuridine, Sigma), followed by a 5 hours incubation with 4 mM hydroxyurea. Afterwards, cells were washed with PBS as previously and harvested by trypsinisation. The cells were counted, diluted to 2.5 x10^5 cells/ml and mixed with unlabelled cells at a 1:1 ratio. Then, 3 μl of the cell suspension was spotted onto a glass slide, 7 μl of Fibre Lysis buffer was added (200 mM Tris-Cl pH 7.4, 50 mM EDTA, 0.5% SDS in sterilised water; filtered) and the drop was pipetted up and down 5 times, avoiding drop expansion. Slides were incubated at RT for 9 minutes and tilted manually at an angle that would allow the drop to slide smoothly to the bottom in 10-15 seconds. Next, the slides were air-dried and fixed overnight in a 3:1 mix of methanol and glacial acetic acid. The slides were then washed in PBS (2 x 3 min) and DNA was denatured in 2.5 M HCl for 1 hour at RT. The slides were washed in PBS (2 x 3 min) and subsequently blocked in freshly prepared Blocking Buffer (1x PBS containing 2% Bovine serum albumin and 0.1% Tween® 20; filtered) for 40 minutes at RT. Next, 60 μl of the primary antibody mix was added on top of the slide and the slide was covered with a cover slip. The slides were incubated at RT for 2.5 hours, before cover slips were carefully removed and the slides were washed with PBST (1x PBS containing 0.2% Tween® 20; 5 x 3 min). Incubation with the secondary antibody mix and washing was done in the same way as for the primary antibody. Subsequently, the slides were air-dried in the dark, mounted with 20 μl of ProLong™ Gold Antifade Mountant.
(Invitrogen), and stored at 4 °C. DNA fibres were visualised (60X objective, IX81, Olympus coupled to a CCD camera, Hamamatsu) and scored using ImageJ.

For each biological replicate 100-200 replication tracts were scored, the IdU/CldU ratio was calculated for each fork, and a Kruskal-Wallis test was employed for statistical analysis within a single experiment. To correct for variations in between experiments, we then normalised the median IdU/CldU ratio for each sample to the experimental control (siControl) within an individual experiment. This value serves to describe the ‘extent of fork degradation’ for a single biological replicate for a given sample.

For the final analysis, the mean extent of fork degradation was determined by dividing the sum of the normalised median IdU/CldU ratios of each sample by the number of biological replicates (3 or more). While not standard in the field we decided to do this because in our view it is necessary to collect data from several independently conducted experiments and perform statistical analysis on biological replicates (individual experiments), rather than technical replicates (individual replication forks within the same sample) to assess a biological phenotype and its significance. The final statistical analysis was done using one-way ANOVA with Sidak’s correction for multiple comparisons. All raw and normalised median values, the number of replication tracks scored and all p-values are reported in Table S1.

**Inhibitors treatment**

For the analysis of replication fork degradation with DNA fibres, mirin (Sigma Aldrich) and PFM01 (Sigma Aldrich) were added to the cells 30 minutes prior the pulse-labelling with thymidine analogues to final concentrations of 50 and 10 μM, respectively, and kept throughout the labelling and hydroxyurea treatment. The DNA2 inhibitor C5 (Aobious Inc.) was used at a final concentration of 20 μM and was added together with hydroxyurea.

**RT-PCR**

For WRNIP1 mRNA analysis, total RNA was extracted from U2OS cells using RNeasy Mini Kit (Qiagen). Then, cDNA synthesis was done using the High Capacity RNA-to-cDNA Kit (Applied Biosystems) according to the manufacturer’s protocol, followed by end-point PCR with WRNIP1-specific primers.

**WRNIP1 sequence alignment**

Primary sequence alignment was done using Clustal Omega algorithm, accessed through the Uniprot website (www.uniprot.org). Accession numbers of aligned proteins were: Q96S55-2 (H. sapiens), Q96S55-1 (H. sapiens), Q91XU0 (M. musculus), Q75JU2 (D. discoideum), P40151 (S. cerevisiae), O13984 (S. pombe) and P0AAZ4 (E. coli).
References

Blastyak, A., Hajdu, I., Unk, I., and Haracska, L. (2010). Role of Double-Stranded DNA Translocase Activity of Human HLTF in Replication of Damaged DNA. Mol. Cell. Biol. 30, 684–693.

Fekairi, S., Scaglione, S., Chahwan, C., Taylor, E.R., Tissier, A., Coulon, S., Dong, M.Q., Ruse, C., Yates, J.R., Russell, P., et al. (2009). Human SLX4 Is a Holliday Junction Resolvase Subunit that Binds Multiple DNA Repair/Recombination Endonucleases. Cell 138, 78–89.

Jackson, D.A., and Pombo, A. (1998). Replicon clusters are stable units of chromosome structure: Evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells. J. Cell Biol. 140, 1285–1295.

Di Marco, S., Hasanova, Z., Kanagaraj, R., Chappidi, N., Altmannova, V., Menon, S., Sedlackova, H., Langhoff, J., Surendranath, K., Hühn, D., et al. (2017). RECQ5 Helicase Cooperates with MUS81 Endonuclease in Processing Stalled Replication Forks at Common Fragile Sites during Mitosis. Mol. Cell 66, 658-671.e8.

Mijic, S., Zellweger, R., Chappidi, N., Berti, M., Jacobs, K., Mutreja, K., Ursich, S., Ray Chaudhuri, A., Nussenzweig, A., Janscak, P., et al. (2017). Replication fork reversal triggers fork degradation in BRCA2-defective cells. Nat. Commun. 8, 859.

Muñoz, I.M., Hain, K., Déclais, A.C., Gardiner, M., Toh, G.W., Sanchez-Pulido, L., Heuckmann, J.M., Toth, R., Macartney, T., Eppink, B., et al. (2009). Coordination of Structure-Specific Nucleases by Human SLX4/BTBD12 Is Required for DNA Repair. Mol. Cell 35, 116–127.

Mutreja, K., Krietsch, J., Hess, J., Ursich, S., Berti, M., Roessler, F.K., Zellweger, R., Patra, M., Gasser, G., and Lopes, M. (2018). ATR-Mediated Global Fork Slowing and Reversal Assist Fork Traverse and Prevent Chromosomal Breakage at DNA Interstrand Cross-Links. Cell Rep. 24, 2629–2642.e5.

Pepe, A., and West, S.C. (2014). MUS81-EME2 Promotes Replication Fork Restart. Cell Rep. 7, 1048 1055.

Przetocka, S., Porro, A., Bolck, H.A., Walker, C., Lezaja, A., Trenner, A., von Aesch, C., Himmels, S.F., D’Andrea, A.D., Ceccaldi, R., et al. (2018). CtIP-Mediated Fork Protection Synergizes with BRCA1 to Suppress Genomic Instability upon DNA Replication Stress. Mol. Cell 72, 568-582.e6.

Thangavel, S., Berti, M., Levikova, M., Pinto, C., Gomathinayagam, S., Vujanovic, M., Zellweger, R., Moore, H., Lee, E.H., Hendrickson, E.A., et al. (2015). DNA2 drives processing and restart of reversed replication forks in human cells. J. Cell Biol. 208, 545–562.

Yuan, J., and Chen, J. (2010). MRE11-RAD50-NBS1 complex dictates DNA repair independent of H2AX. J. Biol. Chem. 285, 1097–1104.